新辅助治疗在食管癌治疗中的作用  

THE VALUE OF NEOADJUVANT THERAPY IN TREATMENTING ESOPHAGEAL CARCINOMA

作　　者：任军[1] 王善政[2] 丛波[2] 栾信庸[3] 章晓梅[1] 

机构地区：[1]山东大学齐鲁医院放疗科 [2]山东大学齐鲁医院胸外科 [3]山东大学齐鲁医院耳鼻喉科

出　　处：《山东医科大学学报》2001年第3期252-253,255,共3页Acta Academiae Medicinae Shandong

摘　　要：目的 :探讨新辅助治疗在食管癌治疗中的作用。方法 :食管癌 2 7例 ,2 2例进入联合化—放疗组 ,给予食管动脉灌注化疗和根治性放疗 6 0～ 70Gy ;5例进入综合治疗组 ,给予食管动脉灌注化疗 +术前放疗 37～ 4 5Gy +肿瘤切除。 结果 :2 7例食管癌患者经食管动脉灌注化疗及根治性或术前放疗后 ,X线检查CR为 4 0 74 % (11/ 2 7) ,PR为 55 56 % (15/ 2 7) ,ST为 3 70 % (1/ 2 7)。综合治疗组有 2例 (2 / 5)切除标本完全无癌。中位生存期在联合化—放疗组为 9个月 ,综合治疗组为 13个月。结论 :化、放疗联合治疗可提高食管癌的局部控制率 ,生存率仍不理想 ;以化、放疗作为新辅助治疗加手术切除的综合疗法 ,可以提高局部控制率 。Objective:To evaluate treatment effect of neoadjuvant therapy between two modalitie using combinations of radiation therapy and chemotherapy,alone or in a preoperative setting,respectively.Methods:Total number of 27 patients with esophageal carcinoma,22 cases were treated for esophageal artery infusion and radical radiation 60～70Gy.Esophagectomy was performed for 5 cases after esophageal artery infusion and preoperative radiation 37～45Gy.Results:Therapy effect was evaluated by X ray examination for all cases,CR:40.74%(11/27),PR:55.56%(15/27),ST:3.70%(1/27),2 cases for resected patients without tumor in the specimen.The median survival were 9 and 13 month,respectively.Conclusion:Chemoirradiation alone improves locoregional control rate,but has little influence on survival rate;Neoadjuvant chemoirradiation combined with surgical resection obttained satisfied locoregional control and survival rate.

关 键 词：食管肿瘤 综合疗法 治疗 疗效 

分 类 号：R735.1[医药卫生—肿瘤]